person · Reporting owner
Selvaraj Shelly Ramasamy
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | SVP Chief Information Officer | September 11, 2023 | September 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date September 11, 2023 · Filed September 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,453 |
Reported balance
After 2023-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-11 · Disposition to issuer · Disposed 2,045 · Balance 48,453 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 22,685 unvested restricted stock units, 10,885 of which were granted on March 8, 2023 and shall all vest on March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 22,685 unvested restricted stock units, 10,885 of which were granted on March 8, 2023 and shall all vest on March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2020 Filed Mar 11, 2020 00:29 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,483 | $0.00 | $5.48 |
DisclosureSEC source: 0001093557-20-000081 · edgardoc.xml · nonDerivative · entry 1 Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,834 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 19,896 unvested restricted stock units, 5,483 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 5,512 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 5,901 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 3,000 of which of were granted on May 22, 2016 and shall vest through May 22, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.